ストックスクリーナーアプリを入手
22.29
2.39%
0.52
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
Newamsterdam pharma's COO sells $3.1 million in stock - MSN
JPMorgan Chase & Co. Acquires 14,280 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co. - Defense World
Newamsterdam pharma CFO sells shares worth $1.5 million - MSN
Newamsterdam pharma CFO sells shares worth $1.5 million By Investing.com - Investing.com UK
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - The Manila Times
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference - GlobeNewswire
Cardiovascular Drug Developer NewAmsterdam Pharma Takes Center Stage at Elite Biotech Conference - StockTitan
Moody Aldrich Partners LLC Lowers Stock Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trials - MSN
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap DownHere's What Happened - MarketBeat
Trend Tracker for (NAMS) - Stock Traders Daily
Royal Bank of Canada Reaffirms “Outperform” Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma's (NAMS) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings) - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC - Defense World
Analysts Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $39.80 - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $39.80 Consensus Price Target from Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9%What's Next? - MarketBeat
NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright - Defense World
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
14 Best 52-Week High Stocks To Buy According to Analysts - Insider Monkey
NewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks Now - Insider Monkey
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC Wainwright - MarketBeat
NewAmsterdam Pharma Company N.V. Issues Press Release and Corporate PresentationOn January 10, 2025, NewAmsterdam Pharma Company N.V. filed a Form 8-K with the Securities and Exchange Commission, highlighting significant achievements in 2 - Defense World
NewAmsterdam gears up for obicetrapib regulatory filings By Investing.com - Investing.com Australia
NewAmsterdam gears up for obicetrapib regulatory filings - Investing.com India
NewAmsterdam Pharma Achieves Key Milestones in 2024 - TipRanks
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - The Manila Times
NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials - StockTitan
Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Grants Equity Awards to New Chief People Officer, Key Hires - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 12-Month HighTime to Buy? - MarketBeat
State Street Corp Purchases 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
State Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World
Nap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Brokers Offer Predictions for NAMS FY2024 Earnings - Defense World
FY2024 Earnings Estimate for NAMS Issued By HC Wainwright - MarketBeat
(NAMSW) On The My Stocks Page - Stock Traders Daily
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com India
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by HC Wainwright - Defense World
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,438 Shares of Stock - MarketBeat
NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular market impact - Investing.com Nigeria
NewAmsterdam Pharma's SWOT analysis: obicetrapib stock poised for cardiovascular market impact By Investing.com - Investing.com South Africa
Newamsterdam Pharma's major shareholders sell shares worth $1.95 million - Investing.com
Obicetrapib’s data positions NewAmsterdam Pharma stock for growth, says H.C. Wainwright - Investing.com Nigeria
Where NewAmsterdam Pharma Stands With Analysts - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at HC Wainwright - MarketBeat
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):